Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOX plus sintilimab neoadjuvant therapy in locally advanced gastric cancer
ChiCTR2400093085Phase 2Not yet recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab, oxaliplatin and tegafur + gimeracil + oteracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Pathological complete response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
sintilimaboxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400093085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093085.